文献速递肿瘤 PET/CT放射性药物与辐射防护

68Ga-NODAGA-MJ9(GRP受体拮抗剂)首次人体辐射剂量学研究

First in-human radiation dosimetry of the gastrin-releasing peptide (GRP) receptor antagonist 68Ga-NODAGA-MJ9.
PubMed 文献 · EJNMMI Res · 2018-12-12

本研究在5例生化复发的男性前列腺癌患者中开展68Ga-NODAGA-MJ9的首次人体剂量学评估,注射后2小时内完成4次全身TOF PET/CT显像,并用OLINDA/EXM 2.0计算器官吸收剂量与有效剂量。结果显示胰腺受照剂量最高,其次为膀胱壁、小肠和肾脏;30分钟排尿周期下男性有效剂量为17.6 μSv/MBq。

要点

  • 胰腺是68Ga-NODAGA-MJ9注射后受照剂量最高的器官。
  • 延长排尿间隔会显著增加膀胱、前列腺和睾丸的吸收剂量及有效剂量。
  • 有效剂量与其他常用68Ga标记肽处于同一范围。

核心结论

  • 胰腺是注射68Ga-NODAGA-MJ9后受照剂量最高的器官,其后依次为膀胱壁、小肠和肾脏。
  • 男性有效剂量与其他常用68Ga标记肽处于同一范围。
  • 与已发表的bombesin类似物研究存在差异,主要取决于吸收剂量计算方法。

研究设计与样本

  • 首次人体剂量学研究,纳入5例连续入组、生化复发的前列腺腺癌男性患者,均属于双示踪剂PET方案。
  • 注射后2小时内完成4次全身飞行时间(TOF)PET/CT扫描。
  • 在脑、甲状腺、肺、心、肝、胆囊、脾、胃、肾、肾上腺、红骨髓、胰腺、肠道、膀胱及全身手动勾画感兴趣区,推导时间积分活度系数。
  • 用OLINDA/EXM 2.0结合NURBS体素化体模(按ICRP-89器官质量和ICRP103组织权重因子调整)计算器官吸收剂量和有效剂量。
  • 另用OLINDA/EXM 1.1进行吸收剂量估算以便与既往类似发表结果比较。

主要发现

  • 吸收剂量最高的体部区域为胰腺、膀胱壁、小肠和肾脏,分别为260、69.8、38.8和34.8 μGy/MBq。
  • 按30分钟排尿周期计算,男性患者的有效剂量为17.6 μSv/MBq。
  • 延长排尿时间间隔使膀胱、前列腺和睾丸的吸收剂量显著增加,同时使有效剂量增加。
  • 用OLINDA/EXM 1.1计算时有效剂量也升高。

关键数值与推荐

  • 胰腺、膀胱壁、小肠、肾脏吸收剂量分别为260、69.8、38.8和34.8 μGy/MBq。
  • 30分钟排尿周期下男性有效剂量为17.6 μSv/MBq。
  • 临床试验注册号:Clinicaltrial.Gov NCT02111954,发布于11/04/2014。

临床怎么用

  • 68Ga-NODAGA-MJ9用于前列腺癌PET显像时,胰腺为关键剂量限制器官,需关注其辐射剂量。
  • 建议按30分钟排尿周期管理患者排尿,以控制膀胱及有效剂量。
  • 与其他68Ga标记肽比较时需注意剂量学计算方法差异对结果的影响。

局限性

  • 样本量仅5例,均为男性生化复发前列腺癌患者。
  • 吸收剂量计算依赖手动勾画感兴趣区及体模调整,与既往研究的方法学差异影响可比性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gastrin-releasing peptide receptor antagonists have promise in theranostics of several highly incident tumours, including prostate and breast. This study presents the first human dosimetry of 68Ga-NODAGA-MJ9 in the first five consecutive patients with recurrent prostate cancer included in a dual-tracer positron emission tomography (PET) protocol. Five male patients with biochemical relapse of prostate adenocarcinoma underwent four whole-body time-of-flight PET/CT scans within 2 h after tracer injection. To be used as input in OLINDA/EXM 2.0, time-integrated activity coefficients were derived from manually drawn regions of interest over the following body regions: brain, thyroid, lungs, heart, liver, gallbladder, spleen, stomach, kidneys, adrenals, red marrow, pancreas, intestines, urinary bladder and whole body. Organ absorbed doses and effective dose (ED) were calculated with OLINDA/EXM 2.0 using the NURBS voxelized phantoms adjusted to the ICRP-89 organ masses and ICRP103 tissue-weighting factors. Additional absorbed dose estimations were performed with OLINDA/EXM 1.1 to be comparable with similar previous publications. RESULTS: The body regions receiving the highest absorbed doses were the pancreas, the urinary bladder wall, the small intestine and the kidneys (260, 69.8, 38.8 and 34.8 μGy/MBq respectively). The ED considering a 30-min urinary voiding cycle was 17.6 μSv/MBq in male patients. The increment of voiding time interval produced a significant increase of absorbed doses in bladder, prostate and testes, as well as an increase of ED. ED also increased if calculated with OLINDA/EXM 1.1. These results have been discussed in view of similar publications on bombesin analogues or on other commonly used theranostic peptides. CONCLUSIONS: The pancreas is the most irradiated organ after the injection of 68Ga-NODAGA-MJ9, followed by the urinary bladder wall, the small intestine and the kidneys. ED is in the same range of other common 68Ga-labelled peptides. Differences with similarly published studies on bombesin analogues exist, and are mainly dependent on the methodology used for absorbed dose calculations. TRIAL REGISTRATION: Clinicaltrial.Gov identifier: NCT02111954 , posted on 11/042014.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Gnesin S, Cicone F, Mitsakis P, et al. First in-human radiation dosimetry of the gastrin-releasing peptide (GRP) receptor antagonist 68Ga-NODAGA-MJ9. EJNMMI Res. 2018. PMID: 30543050. doi:10.1186/s13550-018-0462-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。